Полный текст:
1. World Health Organization: Global status report on noncommuni-cable diseases, 2010 / WHO Press, 2011
2. Jemal A. Cancer statistics, 2009. CA Cancer / А. Jemal, R. Siegel, E. Ward et al. // J. Clin.- 2009.- Vol. 59.- Р 225-249.
3. Barentsz J. O. ESUR prostate MR guidelines 2012 / J. O. Barentsz, J. Richenberg, R. Clements et al. // Eur. Radiol.- 2012.- Vol. 22.- P 746-757.
4. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 2.2014/ NCCN.org
5. Coakley F. V. Radiologic anatomy of the prostate gland: clinical approach / F. V Coakley, H. Hricak // Radiol. Clin. North Am.- 2000.- Vol. 38.- P 15-30.
6. Thompson I. M. Prevalence of prostate cancer among men with prostate-specific antigen level 7. Мищенко А. В. Комплексное магнитно-резонансное исследование в диагностике заболеваний внутренних половых органов у мужчин: дис.. д-ра мед. наук / А. В. Мищенко.- СПб., 2009.
9. Weinreb J. C. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study / J. C. Weinreb, J. D. Blume, F. V Coakley et al. // Radiology.- 2009.- Vol. 122.- Р 91-133.
10. Singh H. Improved detection of clinically significant, curable prostate cancer with systemathic 12-core biopsy / H. Singh, E. I. Canto, S. F. Shariat et al. // J. Urol.- 2004.- Vol. 171.- Р 1089-1092.
11. Dickinson L. Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendation from a European Consensus Meeting / L. Dickinson, U. H. Ahmed, C. Allen et al. // Eure^. Urology.- 2011.- Vol. 59.- P 477-494.
12. Girouin N. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? / N. Girouin, F. Mege-Lechevallier, A. Tonina Senes et al. // Eur. Radiol.- 2007.- Vol. 17.- Р 1498-1509.
13. Дубицкий Д. Л. Возможности высокопольной магнитно-резонансной томографии в дифференциальной диагностике рака предстательной железы: дис.. канд. мед. наук / Д. Л. Дубицкий.- СПб., 2011.
14. Gretzer M. B. PSA markers of prostate cancer detection / M. B. Gretzer, A. W Partin // Urol. Clin North Am.- 2003.- Vol. 30.- Р 677-686.
15. D’Amico A. V. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk diseases / A. V D’Amico, A. A. Renshaw, K. Cote et al. // J. Clin. Oncol.- 2004.- Vol. 22.- Р 3726-3732.
16. Wang L. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms / L. Wang, H. Hricak, M. W. Kattan et al. // Radiology.- 2006.- Vol. 238.- Р 597-603.
17. Haider M. A. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer / M. A Haider, T. H. van der Kwast, J. Tanguay et al. // AJR.- 2007.- Vol. 189.- Р 323-328.
18. Claus F. G. Pretreatment evaluation of prostate cancer: role of MR imaging and H MR spectroscopy / F. G. Claus, H. Hricak, R. R. Hattery // Radiographics.- 2004.- Vol. 24, suppl 1.- S. 167-180.
19. Мищенко А. В. Критерий риска экстракапсулярной экстензии рака предстательной железы по данным МРТ / А. В. Мищенко // Вестник Российской Военно-медицинской академии.- 2009.- № 1 (25).- С. 808.
20. Shimofusa R. Diffusion-weighted imaging of prostate cancer / R. Shimofusa, H. Fujimoto, H. Akamata et al. // J. Comput. Assist Tomogr.- 2005.- Vol. 29.- Р 149-153.
21. Мищенко А. В. Магнитно-резонансные диффузионно-взвешенные изображения при раке предстательной железы / А. В. Мищенко // Кремлевская медицина: клинический вестник.- 2009.- № 3.- С. 64-67.
22. Мищенко А. В. Основы и клиническое применение водородной (протонной) магнитно-резонансной спектроскопии (1Н-МРС) предстательной железы / А. В. Мищенко, Г. Е. Труфанов, Д.Л. Дубицкий // Магнитно-резонансная спектроскопия: Руко водство для врачей / Под ред. Г. Е. Труфанова, Л. А. Тютина.- СПб.: ЭЛБИ-СПб, 2008.- С. 137-164.
23. Jung J. A. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system / J. A. Jung, F. V Coakley, D. B. Vigneron et al. // Raiology.- 2004.- Vol. 233.- Р 701-708.
24. Zakian K. L. Correlation of proton MR spectroscopic imaging with GLEASON score based on step-section pathologic analysis after radical prostatectomy / K. L. Zakian, K. Sircar, H. Hricak et al. // Radiology.- 2005.- Vol. 234.- Р 804-814.
25. Joseph T. Pretreatment endorectal magnetic resonance spectroscopic imaging features of prostate cancer as a predictors of response to external beam radiotherapy / T. Joseph, D. A. McKenna, A. C. Westphalen et al. // Int. J. Radiat. Oncol Biol Phis.- 2009.- Vol. 73.- Р 665-671.
26. Coakley F. V. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging / F. V. Coakley, J. Kurhanewicz, J. Lu et al. // Radiology.- 2002.- Vol. 223.- Р 91-97.
27. Мищенко А. В. Магнитно-резонансная спектроскопия при контроле эффективности гормональной терапии рака предстательной железы / А. В. Мищенко, Г. Е. Труфанов, С. Б. Петров, E. А. Москаленко // Вестник Российской Военно-медицинской академии.- 2009.- № 2 (26).- С. 44-48.
28. Sato C. Differentiation of noncancerous tissue peripheral zones of the prostate / C. Sato, T. Nakamura et al. // J. Magn. Reson. Imaging.- 2005.- Vol. 21.- Р. 258-262.
29. Kitajima K. High b-value diffusion-weighted imaging in normal and malignant peripheral zone tissue of prostate: effect of signal-to-noise ratio / K. Kitajima, Y. Kaji, K. Kuroda, K. Sugimura // Magn. Reson. Med. Sci.- 2008.- Vol. 7.- Р 93-99.
30. Мищенко А. В. Магнитно-резонансные диффузионно-взвешенные изображения при раке предстательной железы / А. В. Мищенко // Кремлевская медицина: клинический вестник.- 2009.- № 3.- С. 64-67.
31. Lim H. K. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection — a multireader study / H. K. Lim, K. A Kim, K. S. Chao // Radiology.- 2009.- Vol. 250.- Р 145-151.
32. Buckley D. L. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging-initial experience / D. L. Buckley, C. Roberts, G. J. Parker et al. // Radiology.- 2004.- Vol. 233.- Р 709-715.
33. Choi Y. J. Functional MR imaging of prostate cancer / Y. J. Choi, J. K. Kim, K. W. Kim et al. // RadioGraphics.- 2007.- Vol. 27.- Р 63-75.
34. Engelbrecht M. R. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging / M. R. Engelbrecht, H. J. Huisman, R. J. Laheij et al. // Radiology.- 2003.- Vol. 229.- Р 248-254.
35. Мищенко А. В. Факторы, определяющие показатели динамического контрастирования очага аденокарциномы предстательной железы при магнитно-резонансной томографии / А. В. Мищенко // Вестник Российской Военно-медицинской академии.- 2009.- № 1 (25).- С. 808-809.
Контент доступен под лицензией Creative Commons Attribution 4.0 License.
Полный текст:
197758, Санкт-Петербург, пос. Песочный, ул. Ленинградская,68;
199034, Санкт-Петербург, Университетская наб., 7–9
руководитель отдела лучевой диагностики, д.м.н.,
125284, Москва, 2-й Боткинский проезд, 3
1. Thornbury J.R., Ornstein D.K., Choyke P.L. et al. Prostate Cancer: What is the future for imaging? Am J Roentgenology 2001;176:17–22.
2. Engelhard K., Hollenback H.P., Deimiing M. et al. Combination of signal intensity measurements of lesions in the peripheral zone of prostate with MRI and serum PSA level for differentiating benign disease from prostate cancer. Eur Radiol 2000;10(12);1947–53.
3. Rosenkrantz A.B., Kim S., Lim R.P. et al. Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert Scales. Radiology 2013:269:482–92.
4. Moore C.M., Kasivisvanathan V., Eggener S. et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an international working group. European Urology 2013;64:544–52.
5. Roethke M.C., Kuru T.H., Schultze S. et al. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla. European Radiol 2014;24(2): 344–52.
6. de Rooij M., Hamoen E.H.J., Futterer J.J. et al. Accuracy of muliparametric MRI for prostate cancer detection: a meta-analysis. Am J Roentgenology 2014;202:343–51.
7. Dickinson L., Ahmed H.U., Allen C. et al. Scoring systems used for the interpretation and reporting of mulitparametric MRI for prostate cancer detection, localization and chanarcterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson imaging 2013;37:48–58.
8. Cornud F., Khoury G., Bouazza N. et al. Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation? J Urol 2014;191(5):1272–9.
9. Barentsz J.O., Richenberg J., Clements R. et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012;22:746–57.
10. Rothke M., Blondin D., Schlemmer H.P., Franiel T. PI-RADS- Klassifikation: Strukturiertes Befundungsschema für die MRT der Prostata. Fortschr Rontgenstr 2013;185(3):253–61.
12. Barrett T., Turkbey B., Choyke P.L. PI-RADS version 2: what you need to know. Clinical Radiology 2015;70(11):1165–76.
13. Kuru T.H., Roethke M.C., Rieker P. et al. Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate. BJU Int 2013;112(8):1080–7.
14. Thoeny H.C., Froeliich J.M., Triantafyllou M. et al. Metastases in norma-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging. Radiology 2014;273:125–35.
15. McNeal J.E. The Zonal anatomy of the prostate. The Prostate 1981;2:35–49.
16. Puech P., Rouviere O., Renard-Penna R. et al. Prostate cacner diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal U-MR fusion guidance versus systemeic biopsy-prospective mulitcenter study. Radiology 2013: 268;461–9.
17. Vargas H.A., Hötker A.M., Goldman D.A. et al. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol 2015, Sep. 22.
18. Niaf E., Lartizien C., Bratan F. et al. Prostate focal peripheral zone lesions; characterization at multiparametric MR imaging-influence of computer-aided diagnosis system. Radiology 2014;271:761–9.
19. Somford D.M., Hamoen E.H., Futterer J.J. et al. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. J Urol 2013;190(5):1728–34.
20. Ren J., Yang Y., Zhang J. et al. T(2)-weighted combined with diffusion-weighted images for evaluating prostatic transition zone tumors at 3 Tesla. Future Oncol 2013;9(4):585–93.
21. Akin O., Sala E., Moskowitz C.S. et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006;239(3):784–92.
22. Tamada T., Kanomata N., Sone T. et al. High b value (2,000 s/mm2) diffusion weighted magnetic resonance imaging in prostate cancer at 3 Tesla: comparison with 1,000 s/mm2 for tumor conspicuity and discrimination of aggressiveness. PLOS ONE 2014;9(5).
23. Grant K.B., Agarwal H.K., Shih J.H. et al. Comparison of calculated and acquired high b value diffusion-weighted imaging in prostate cancer. Abdom Imaging 2015;40(3):578–86.
24. Bittencourt L.K., Attenberger U.I., Lima D. et al. Feasibility study of computed vs measured high b-value (1400 s/mm(2)) diffusion-weighted MR images of the prostate. World J Radiol 2014;6(6):374–80.
25. Maas M.C., Futterer J.J., Scheenen T.W. Quantitative evaluation of computed high B value diffusion weighted magnetic resonance imaging of the prostate. Invest Radiol 2013;48(11):779–86.
26. Medved M., Soylu-Boy F.N., Karademir I. et al. High-resolution diffusion-weighted imaging of the prostate. AJR 2014:203:85–90.
27. Iwazawa J., Mitani T., Sassa S., Ohue S. Prostate cancer detection with MRI: is dynamic contrast enhanced imaging necessary in addition to diffusion-weighted imaging? Diagn Interv Radiol 2011;17(3):243–8.
28. Dickinson L., Ahmed H.U., Allen C. et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011;59(4): 477–94.
29. Hamoen E.H., de Rooij M., Witjes J.A. et al. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: A diagnostic meta-analysis. Eur Urol 2015;67(6): 1112–21.
Контент доступен под лицензией Creative Commons Attribution 4.0 License.